Dashboard

Kadmon Holdings, Inc. (KDMN)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

B

Industry Comparison

H

Management & Equity

S

Analyst Opinion

S

Leverage & Liquidity

B

Fundamental Variables

H

Rating Performance

FV Performance

*There is a current rating on the stock that is included in these numbers based on its performance so far

About

Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics. It focuses on the treatment of autoimmune, inflammatory, and fibrotic diseases. Its products include Ribasphere, RibaPak, Tetrabenazine, Valganciclovir, Abacavir, Entecavir, Lamivudine, and Zidovudine. The company was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY.

CEO

Harlan W. Waksal

Employees

115

Industry

Transplantation Biopharmaceuticals

Sector

Healthcare

Headquarters

New York

Exchange

New York Stock Exchange

Summary Stats

Market Cap

1.7B

Revenue

16.1M

Net Income

-122M

EPS

-$0.71

Price-to-Earnings

-13.43

Price-to-Book

126.26

Debt-to-Equity

21.65

News

Analyst Ratings

Price targets projected by 6 analysts

High

$25.00

Average

$12.67

Low

$8.00

Ratings calculated by 0 analysts

Buy

0

Hold

0

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q3 2021

Last Earnings

Missed by $0.00

Actual

-$0.20 +-0.0%

Consensus

-0.2

Report Date

Year Ago

-0.15

Year Ago Change %

Down 33%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites